Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO), in partnership with GHO Capital, announced a major €35 million investment for expansion across its European operations.

The investment will future proof offerings for the biopharma and emerging biotechnology sectors and positions Ardena to become a leading global CDMO, offering end-to-end solutions spanning the full pharma development lifecycle.

Ardena will significantly expand drug product services in Belgium and aseptic fill and finish capabilities for the development and clinical production of small molecule, injectable formulations. Capacity for large molecule biologics will expand to include Peptides, Oligonucleotides (DNA, recombinant RNA, synthetic RNA, RNA vaccines) and Proteins.

This will provide clients with a full-service solution from formulation development, analytical method development and validation, demo batch production, stability studies, GMP batch production, QC testing, labelling and randomization, QP release, storage and shipping through to regulatory support.

The Swedish facility will undergo expansion to support the commercialization of COVID-19 vaccines and further growth of the API business. This will enable more preparative chromatography and HPLC and further expansion of advanced and specialized filtration technology along with lyophilization capacity for bulk quantities.

The investment program will see major improvements in the Netherlands facility, continuing the growth of the API and Nanomedicine activities. This will include the expansion of cleanroom space (Grade D and C), chemical manufacturing capacity, warehouse space, adding chemistry and analytical labs and investing in new technologies to support Ardena’s leadership in Nanotechnology.

“The significant investment in our expansion is a result of our continued outperformance of the market,” said Harry Christiaens, Ardena CEO. “Our focus on the exciting world of early phase development at an international level has proven to be highly successful. We have a great deal of scientific expertise and will continue to invest in the people and resources we need to deliver for our clients.”

“This an exciting time to be at Ardena,” explained Gerjan Kemperman, Ardena COO. “We have the international experience and network to expertly manage multiple projects, whatever the demands of the market or the technologies required.”